Keyword
in
Collection
Date
to
Montrose Voice, No. 325-B, January 16, 1987
File 009
Citation
MLA
APA
Chicago/Turabian
Montrose Voice, No. 325-B, January 16, 1987 - File 009. 1987-01-16. University of Houston Libraries. University of Houston Digital Library. Web. September 21, 2020. https://digital.lib.uh.edu/collection/montrose/item/1465/show/1448.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

(1987-01-16). Montrose Voice, No. 325-B, January 16, 1987 - File 009. Montrose Voice. University of Houston Libraries. Retrieved from https://digital.lib.uh.edu/collection/montrose/item/1465/show/1448

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

Montrose Voice, No. 325-B, January 16, 1987 - File 009, 1987-01-16, Montrose Voice, University of Houston Libraries, accessed September 21, 2020, https://digital.lib.uh.edu/collection/montrose/item/1465/show/1448.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

URL
Embed Image
Compound Item Description
Title Montrose Voice, No. 325-B, January 16, 1987
Contributor
  • McClurg, Henry
  • Wyche, Linda
Publisher Community Publishing Company
Date January 16, 1987
Language English
Subject
  • LGBTQ community
  • LGBTQ people
  • Gay liberation movement
Place
  • Houston, Texas
Genre
  • newspapers
Type
  • Text
Identifier OCLC: 22329406
Collection
  • University of Houston Libraries Special Collections
  • LGBT Research Collection
  • Montrose Voice
Rights In Copyright
Note This item was digitized from materials loaned by the Gulf Coast Archive and Museum (GCAM).
Item Description
Title File 009
Transcript 8 MONTROSE VOICE/JANUARY 16, 1987 Ribaviran Testing to Continue in Houston By Sheri Cohen Darbonne Montrose Voice Testing ofthe experimental drug ribaviran. also called virazole, will continue on Houston patients previously enrolled in a six-month study of the drug. Dr. Peter Mansell, medical director of the Institute for Immunological Disorders, announced Monday. Results of the study, conducted at research centers across the country, were released Friday, Jan. 9, in Washington, D.C. Ribavirin, which interferes with the replication of HIV virus that causes AIDS, appears to at least slow the progression to full-blown AIDS in patients with Lymphadenopathy syndrome, or LAS. Of 163 patients with LAS in the national study, 52 were given a daily dose of 800 milligrams of the drug; 55 were given a lower dose of 600 milligrams and 56 were given a placebo. Ten patients in the placebo group and six in the group receiving 600 milligrams developed AIDS, while none who received the higher dose progressed to AIDS as defined by the National Centers for Disease Control, Mansell said. In Houston, 47 patients at M.D. Anderson Hospital and (after its opening Sept. 2, 1986) the Institute for Immunological Disorders were involved in the study. Of these, six in a placebo group developed AIDS. One patient who received 600 milligrams of ribavirin daily went on to develop the disease. Mansell acknowledged "some possible objections" to the statistics in the placebo group. Three of the patients who got AIDS developed the disease early on in the study, indicating they may have already had it; two actually did not develop full-blown AIDS until after the technical conclusion date of the trial. However, he pointed out that in terms of "significant events," such as opportunistic infections, the results of the test were even more favorable for the drug. In the placebo group, 17 significant events were recorded and 10 appeared in the low-dose group, while none of the patients taking 800 milligrams daily developed significant infections. Another advantage of ribavirin, according to Mansell, is its low toxicity. Only mild side effects, including insomnia and gastrointestinal discomfort, were reported in the group taking the higher dose. Other side effects of the orally-administered drug could be noticed in trials of ribavirin on "sicker" patients, or at higher doses, Mansell noted. The drug's manufacturer, Viratek, Inc., a division of ICN Pharmaceuti cals, has not yet applied for Investigative New Drug status because the FDA has only had data on the tests for a few days, Mansell said. "It's important not to rush these federal agencies," he commented. The FDA is in the process of reviewing and analyzing the test results, he said. When. and how widely, ribavirin is made available depends on how the FDA chooses to respond to the drug company, he said. There are three directions the agency could take in its decision, Mansell explained. He said he favored a "treatment IND," which would make the drug available for use on I_AS patients only. The FDA could also approve the drug for general access and use for a variety of indications, or it could decide not to approve the drug at all. A separate trial of the drug's effects on patients with AIDS-related complex (ARC) will be completed in mid- February, but the results will probably not be available until April, Mansell said. Testing of the drug on AIDS patients was begun in Boston. The drug does not appear to do anything to restore a damaged immune system, hut may slow immune decline although the latter has not been proved. The researchers still do not know what, if any, effect ribavirin has on the HIV virus, Mansell said. Mansell dismissed as "nonsense" accusations that the pharmaceutical company and research team released the test results too early. The results had to be released for three reasons, he said. "The investigators involved in the study had to tell their patients what they were getting. It was no longer ethical to keep this information from them," Mansell said. Also, the FDA requires pharmaceutical companies to disclose such information, and the Securities and Exchange Commission requires companies to make available any information that could affect their stock rating, he added. All patients involved in the local study were offered the opportunity to go on the 800-milligram dose of the drug. About 40 patients at the institute are now on ribavirin, Mansell said. Besides Mansell, the researchers involved in the national ribavirin trial were Dr. Richard Roberts, New York Hospital, Cornell University Medical Center; Dr. Gordon Dickinson, University of Miami: Dr. Peter Heseltine and Dr.John I_eedom, Los Angeles County/ University of Southern California Medical Center, Los Angeles. MAYAN WEAVING DEMONSTRATION SATURDAY, JANUARY 24 Celebrate Mayan culture with Fidelia Mendoza, a Tzutuhil Indian from Guatemala as she weaves her magic in our store. JAZZ UP JANUARY SALE January 24 - •31 Put an exotic flavor in your life with crafts from Central America & the Philippines. Get great deals on handwoven tablecloths, palm hats, baskets & bags, exquisite weavings, hammocks, kid's goods and more. Pueblo to People * 523-1197 1616 Montrose (at W Cray) Mon-Sat 10 am - 6 pm Mention this ad and get a FREE wristband. PARKWAY ATHLETIC CLUB $20,000 OF NEW EQUIPMENT INCREDIBLE FACILITY INCREDIBLE EQUIPMENT INCREDIBLE PRICES INTRODUCTORY OFFER I Bring us your present gym con- Itract from any other gym and we| I will honor the balance of the prepaid time with the purchase ofl [equal time from Parkway Athletic| Club. (Offer expires January 30) • Kucquciball Handball Civ • Nautilus & Tree Weights • Aerobics Studio • Gymnasium Basketball / Volleyball • Barber Shop • Tanning Solarium* • I'ull Linen Service \ • Pro Shop • locker Room, Steam Room. Saunas & Whirlpool Spa I. • Massage Room \ • Rental Lockers • Nutrition Classes • Juice Bar • Meeting / Conference Room Memberships starting at $35°° No Start-Up Fee TANNING 30 minutes for $4.50 800 Rosine St. • Houston • 528-5467
File Name uhlib_22329406_n325b_008.jpg